UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 576

Sortiert nach

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients

Cancer treatment reviews, 2017-09, Vol.59, p.93-101

Janku, Filip

2017

Volltextzugriff (PDF)

Targeting the PI3K pathway in cancer: are we making headway?

Nature reviews. Clinical oncology, 2018-05, Vol.15 (5), p.273-291

2018

Volltextzugriff (PDF)

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Pharmacology & therapeutics (Oxford), 2014-05, Vol.142 (2), p.164-175

2014

Volltextzugriff (PDF)

Tumor heterogeneity in the clinic: is it a real problem?

Therapeutic Advances in Medical Oncology, 2014-03, Vol.6 (2), p.43-51

Janku, Filip

2014

Volltextzugriff (PDF)

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

Cancers, 2021-07, Vol.13 (14), p.3600

2021

Volltextzugriff (PDF)

Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma

Journal of clinical oncology, 2020-10, Vol.38 (29), p.3398-3406

2020

Volltextzugriff (PDF)

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

Journal of clinical oncology, 2015-09, Vol.33 (25), p.2753-2762

2015

Volltextzugriff (PDF)

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Clinical cancer research, 2021-08, Vol.27 (16), p.4491-4499

2021

Volltextzugriff (PDF)

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

Blood, 2014-07, Vol.124 (4), p.483-492

2014

Volltextzugriff (PDF)

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

Scientific reports, 2021-02, Vol.11 (1), p.3667-3667, Article 3667

2021

Volltextzugriff (PDF)

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (13), p.3690-3701

2016

Volltextzugriff (PDF)

Associations between the gut microbiome and fatigue in cancer patients

Scientific reports, 2021-03, Vol.11 (1), p.5847-5847, Article 5847

2021

Volltextzugriff (PDF)

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications

PloS one, 2014-12, Vol.9 (12), p.e115383-e115383

2014

Volltextzugriff (PDF)

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers

Molecular cancer therapeutics, 2018-07, Vol.17 (7), p.1595-1601

2018

Volltextzugriff (PDF)

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Clinical cancer research, 2018-01, Vol.24 (1), p.181-188

2018

Volltextzugriff (PDF)

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Journal of clinical oncology, 2012-03, Vol.30 (8), p.777-782

2012

Volltextzugriff (PDF)

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Cancer discovery, 2016-02, Vol.6 (2), p.154-165

2016

Volltextzugriff (PDF)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Scientific reports, 2022-05, Vol.12 (1), p.8701-8701, Article 8701

2022

Volltextzugriff (PDF)

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

The lancet oncology, 2014-05, Vol.15 (6), p.656-666

2014

Volltextzugriff (PDF)

A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA

Scientific reports, 2021-10, Vol.11 (1), p.19653-19653, Article 19653

2021

Volltextzugriff (PDF)

First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer

Investigational new drugs, 2021-10, Vol.39 (5), p.1348-1356

2021

Volltextzugriff (PDF)

ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi18-vi18

2018

Volltextzugriff (PDF)

1 – 25 von 576

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(523)
Mit Volltextzugriff
(562)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(231)
Life Sciences & Biomedicine
(217)
Humans
(203)
Oncology
(195)
Female
(141)
Middle Aged
(130)
Male
(125)
Adult
(121)
Aged
(116)
Mutation
(86)
Tumors
(67)
Cancer
(63)
Aged, 80 And Over
(60)
Treatment Outcome
(59)
Patients
(55)
Neoplasms - Drug Therapy
(54)
Young Adult
(52)
Neoplasms - Genetics
(42)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(41)
Medicine
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(167)
Cancer Research
(81)
Molecular Cancer Therapeutics
(38)
Oncotarget
(33)
Clinical Cancer Research
(25)
Investigational New Drugs
(17)
Journal For Immunotherapy Of Cancer
(17)
The Oncologist
(11)
Cancer Chemotherapy And Pharmacology
(10)
The oncologist
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients

Targeting the PI3K pathway in cancer: are we making headway?

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Tumor heterogeneity in the clinic: is it a real problem?

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Associations between the gut microbiome and fatigue in cancer patients

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA

First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer

ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION

Suchergebnisse filtern